Information Journal Paper
APA:
Copy. (2021). COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. LANCET RESPIRATORY MEDICINE, 9(12), 0-0. SID. https://sid.ir/paper/1012465/en
Vancouver:
Copy. COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. LANCET RESPIRATORY MEDICINE[Internet]. 2021;9(12):0-0. Available from: https://sid.ir/paper/1012465/en
IEEE:
Copy, “COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial,” LANCET RESPIRATORY MEDICINE, vol. 9, no. 12, pp. 0–0, 2021, [Online]. Available: https://sid.ir/paper/1012465/en